

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

- 1-14. (cancelled herein).
15. (currently amended) An isolated antibody that immunospecifically-binds to an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 5 the polypeptide of claim 1.
16. (original) The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. (original) The antibody of claim 15, wherein the antibody is a humanized antibody.
- 18-34. (cancelled herein).
35. (currently amended) A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
- 36-37. (cancelled herein).
38. (currently amended) A kit comprising in one or more containers, the pharmaceutical composition of claim 35.
- 39-48. (cancelled herein).
49. (newly added) An isolated antibody that immunospecifically-binds to an isolated polypeptide comprising an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO: 5, wherein said polypeptide has kinase activity.
50. (newly added) The antibody of claim 49, wherein said antibody is a monoclonal antibody.
51. (newly added) The antibody of claim 49, wherein the antibody is a humanized antibody.
52. (newly added) A composition comprising the antibody of claim 49 and a pharmaceutically-acceptable carrier.
53. (newly added) A kit comprising in one or more containers, the composition of claim 52.
54. (newly added) An isolated antibody that immunospecifically-binds to an isolated polypeptide comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 5, wherein said polypeptide has kinase activity.
55. (newly added) The antibody of claim 54, wherein said antibody is a monoclonal antibody.

56. (newly added) The antibody of claim 54, wherein the antibody is a humanized antibody.
57. (newly added) A composition comprising the antibody of claim 54 and a pharmaceutically-acceptable carrier.
58. (original) A kit comprising in one or more containers, the composition of claim 57.
59. (newly added) An isolated antibody that immunospecifically-binds to an isolated polypeptide comprising amino acids 28-992 of SEQ ID NO: 5.
60. (newly added) The antibody of claim 59, wherein said antibody is a monoclonal antibody.
61. (newly added) The antibody of claim 59, wherein the antibody is a humanized antibody.
62. (newly added) A composition comprising the antibody of claim 59 and a pharmaceutically-acceptable carrier.
63. (newly added) A kit comprising in one or more containers, the composition of claim 62.
64. (newly added) An isolated antibody that immunospecifically-binds to an isolated polypeptide variant of the amino acid sequence of SEQ ID NO: 5, wherein one amino acid residue in said variant differs from the amino acid sequence of SEQ ID NO: 5, wherein said polypeptide variant has kinase activity.
65. (newly added) The antibody of claim 64, wherein said antibody is a monoclonal antibody.
66. (newly added) The antibody of claim 64, wherein the antibody is a humanized antibody.
67. (newly added) A composition comprising the antibody of claim 64 and a pharmaceutically-acceptable carrier.
68. (newly added) A kit comprising in one or more containers, the composition of claim 67.
69. (newly added) An isolated antibody that immunospecifically-binds to an isolated polypeptide comprising the mature form of the amino acid sequence of SEQ ID NO: 5.
70. (newly added) The antibody of claim 69, wherein said antibody is a monoclonal antibody.
71. (newly added) The antibody of claim 69, wherein the antibody is a humanized antibody.
72. (newly added) A composition comprising the antibody of claim 69 and a pharmaceutically-acceptable carrier.
73. (newly added) A kit comprising in one or more containers, the composition of claim 72.